Sepio Capital, LP Amgen Inc Transaction History

Sepio Capital, LP

$936 Million
Q2 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 03, 2023	SELL	$229.03 - $291.01 $1.7 Million - $2.17 Million	-7,442 Reduced 90.41%	789 $207,000
Q3 2022 Oct 28, 2022	BUY	$224.46 - $253.15 $1.85 Million - $2.08 Million	8,231 New	8,231 $1.86 Million
Q3 2021 Nov 03, 2021	SELL	$212.27 - $248.7 $2.37 Million - $2.78 Million	-11,177 Closed	0 $0
Q2 2021 Jul 26, 2021	BUY	$233.58 - $259.14 $1.38 Million - $1.53 Million	5,892 Added 111.49%	11,177 $2.72 Million
Q1 2021 May 10, 2021	BUY	$221.91 - $258.6 $1.17 Million - $1.37 Million	5,285 New	5,285 $1.32 Million
Q4 2020 Feb 10, 2021	SELL	$216.38 - $257.67 $1.26 Million - $1.5 Million	-5,836 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$234.65 - $260.95 $17,598 - $19,571	-75 Reduced 1.27%	5,836 $1.48 Million
Q2 2020 Aug 04, 2020	SELL	$197.81 - $242.74 $2.66 Million - $3.27 Million	-13,459 Reduced 69.48%	5,911 $1.39 Million
Q1 2020 Apr 29, 2020	BUY	$182.24 - $241.7 $304,340 - $403,639	1,670 Added 9.44%	19,370 $3.93 Million
Q4 2019 Feb 06, 2020	SELL	$189.21 - $243.2 $54,492 - $70,041	-288 Reduced 1.6%	17,700 $4.27 Million
Q3 2019 Oct 25, 2019	BUY	$174.11 - $208.62 $581,005 - $696,164	3,337 Added 22.78%	17,988 $3.5 Million
Q2 2019 Aug 08, 2019	SELL	$166.7 - $195.41 $196,205 - $229,997	-1,177 Reduced 7.44%	14,651 $2.7 Million
Q1 2019 Jun 21, 2019	BUY	$180.87 - $203.88 $759,654 - $856,296	4,200 Added 36.12%	15,828 $3.02 Million
Q1 2019 May 14, 2019	SELL	$180.87 - $203.88 $1.51 Million - $1.7 Million	-8,322 Reduced 41.71%	11,628 $2.21 Million
Q4 2018 Feb 13, 2019	BUY	$178.4 - $208.25 $3.56 Million - $4.15 Million	19,950 New	19,950 $3.88 Million

Others Institutions Holding AMGN

# of Institutions

3,075

Shares Held

417M

Call Options Held

7.19M

Put Options Held

6.28M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $169B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sepio Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Sepio Capital, LP with notifications on news.

Account